mabcute: rituximab maintenance in r/r indolent nhl
Published 5 years ago • 164 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:37
mabcute results: extended subcutaneous r maintenance for indolent nhl
-
2:47
golcadomide ± rituximab for r/r nhl: phase i/ii trial interim analysis
-
1:55
ibrutinib in combination with rituximab – the future of treating fl
-
0:46
a novel agent bi-1206 in combination with rituximab in indolent nhl
-
6:38
ivac /- rituximab in r/r b-nhls: a real-world data review
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
21:38
drawing the line: the rationale behind blood tube collection order
-
6:54
biomarker-guided treatment of cll in the chemo-free era
-
3:15
updates on the use of btkis in the treatment of mcl
-
1:26
adverse events associated with btkis in the treatment of waldenström’s macroglobulinemia
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
2:10
ilyad study: vitamin d supplementation in low tumor-burden indolent nhl treated with rituximab
-
1:08
top-flor: treatment of newly-diagnosed fl with golcadomide, rituximab /- nivolumab
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
1:35
update on phase i study of plamotamab in r/r nhl
-
4:19
a single-cell rna analysis of tumor and immune cells in asymptomatic and overt wm
-
1:21
the role of chemoimmunotherapy in the era of targeted therapies for wm
-
1:45
managing cardiovascular risks in patients with chip and mpns: insights from a cardiologist
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
2:32
tools and biomarkers being used for the diagnosis of bpdcn
-
2:15
muk seven biomarker trial: prognostic molecular stratification in r/r mm